Medtronic, Inc. Files for FDA Approval of Drug-Eluting Balloon
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Medtronic files the 1st module of a pre-market approval application with the FDA for its In.Pact Admiral drug-eluting balloon to treat peripheral artery disease. Medtronic (NYSE:MDT) applied for pre-market approval from the FDA for a medical device designed to treat peripheral artery disease, the In.Pact Admiral drug-eluting balloon. Fridley, Minn.-based Medtronic said it's gearing up for a full launch in the U.S. in 2015, assuming the FDA approves the application.
Help employers find you! Check out all the jobs and post your resume.
Medtronic files the 1st module of a pre-market approval application with the FDA for its In.Pact Admiral drug-eluting balloon to treat peripheral artery disease. Medtronic (NYSE:MDT) applied for pre-market approval from the FDA for a medical device designed to treat peripheral artery disease, the In.Pact Admiral drug-eluting balloon. Fridley, Minn.-based Medtronic said it's gearing up for a full launch in the U.S. in 2015, assuming the FDA approves the application.
Help employers find you! Check out all the jobs and post your resume.